score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CCNE1	Amplification				0.0	0.0		Putatively Actionable	Bortezomib	Proteasome inhibition	Targeted therapy	Sensitivity to Bortezomib was observed in ovarian cancer cell lines.	"Etemadmoghadam, Dariush, et al. ""Synthetic lethality between CCNE1 amplification and loss of BRCA1."" Proceedings of the National Academy of Sciences 110.48 (2013): 19489-19494."	https://doi.org/10.1073/pnas.1314302110													0				CCNE1 Amplification	1.0	Osteosarcoma-SJDOSTEOS013	SJDOSTEOS013-1	
Putatively Actionable		Clinical evidence		Copy Number	CRKL	Amplification				0.0	0.0									Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	CRKL amplification was observed in an EGFR inhibitor resistant tumor after researchers observed that cells from gefitinib-sensitive cell line (HCC827) overexpressing CRKL became resistant to gefitinib relative to controls.	Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1(7):608-25.	https://doi.org/10.1158/2159-8290.CD-11-0046						0				CRKL Amplification		Osteosarcoma-SJDOSTEOS013	SJDOSTEOS013-1	
Putatively Actionable			Guideline	Copy Number	TP53	Deletion				0.0	0.0																Putatively Actionable	0.0	Deletion of 17p13 leads to LoH of TP53 and is considered a high-risk feature of multiple myeloma.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	0				TP53 Deletion		Osteosarcoma-SJDOSTEOS013	SJDOSTEOS013-1	
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.301						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683													0				COSMIC Signature (version 2) 3 (30%)		Osteosarcoma-SJDOSTEOS013		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						Osteosarcoma-SJDOSTEOS013		
Biologically Relevant				Somatic Variant	MTOR	Missense	p.M1174I	0.0941	85.0	0.0	0.0																					0				MTOR p.M1174I (Missense)		Osteosarcoma-SJDOSTEOS013	Osteosarcoma-SJDOSTEOS013-Tumor	Osteosarcoma-SJDOSTEOS013-Normal
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S593R	0.0256	508.0	0.0	0.0																					0				BRD4 p.S593R (Missense)		Osteosarcoma-SJDOSTEOS013	Osteosarcoma-SJDOSTEOS013-Tumor	Osteosarcoma-SJDOSTEOS013-Normal
Biologically Relevant				Copy Number	BRD4	Amplification				0.0	0.0																					0				BRD4 Amplification		Osteosarcoma-SJDOSTEOS013	SJDOSTEOS013-1	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)		Osteosarcoma-SJDOSTEOS013		
